We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
+11.82%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$252M
AUM Growth
-$117M
Cap. Flow
-$61.6M
Cap. Flow %
-24.44%
Top 10 Hldgs %
67.87%
Holding
57
New
9
Increased
3
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.6M
2
MMS icon
Maximus
MMS
+$13.9M
3
ANNX icon
Annexon
ANNX
+$8.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$7.07M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$4.66M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$16.8M
2
LH icon
Labcorp
LH
+$16M
3
SNN icon
Smith & Nephew
SNN
+$14.4M
4
OGN icon
Organon & Co
OGN
+$12.6M
5
GSK icon
GSK
GSK
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 78.37%
2 Miscellaneous 11.54%
3 Industrials 5.73%
4 Consumer Staples 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
1
Labcorp
LH
$27.2B
$38.7M 15.36%
173,293
-72,609
-30% -$16M
ISRG icon
2
PUT
Intuitive Surgical
ISRG
$132B
$29M 11.49%
+59,000
New +$27.5M
TEVA icon
3
Teva Pharmaceuticals
TEVA
$42.5B
$24.3M 9.64%
+1,349,274
New +$23.6M
MMS icon
4
Maximus
MMS
$3.13B
$14.5M 5.73%
+155,142
New +$13.9M
ZBH icon
5
Zimmer Biomet
ZBH
$19.2B
$13.8M 5.46%
127,511
-27,793
-18% -$3.03M
VXRT
6
DELISTED
Vaxart
VXRT
$11.6M 4.58%
13,608,244
-1,156,747
-8% -$884K
KVUE icon
7
Kenvue
KVUE
$36.8B
$11M 4.35%
474,741
-10,259
-2% -$213K
TFX icon
8
Teleflex
TFX
$5.92B
$9.71M 3.85%
39,272
-71,806
-65% -$16.8M
TYRA icon
9
Tyra Biosciences
TYRA
$1.49B
$9.42M 3.74%
400,870
-199,424
-33% -$4.19M
IRON icon
10
Disc Medicine
IRON
$3.07B
$9.24M 3.66%
187,941
-4,059
-2% -$191K
CI icon
11
Cigna
CI
$73.7B
$9.18M 3.64%
26,503
-283
-1% -$97.4K
ANNX icon
12
Annexon
ANNX
$942M
$8.48M 3.36%
+1,433,155
New +$8.5M
BDSX icon
13
Biodesix
BDSX
$283M
$7.72M 3.06%
216,926
-467
-0.2% -$16.1K
RLAY icon
14
Relay Therapeutics
RLAY
$4.11B
$6.7M 2.66%
+945,839
New +$7.07M
ERAS icon
15
Erasca
ERAS
$6.31B
$6.06M 2.4%
2,219,186
-655,350
-23% -$1.85M
CMPS
16
Compass Pathways
CMPS
$1.9B
$5.76M 2.29%
914,639
+621,222
+212% +$4.38M
ATXS
17
DELISTED
Astria Therapeutics
ATXS
$5.56M 2.2%
504,887
-5,380
-1% -$59.8K
PMVP icon
18
PMV Pharmaceuticals
PMVP
$65.2M
$4.79M 1.9%
3,214,239
+505,831
+19% +$782K
VTYX
19
DELISTED
Ventyx Biosciences
VTYX
$4.3M 1.7%
1,971,948
+1,193,024
+153% +$2.74M
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.87B
$3.9M 1.55%
+123,000
New +$4.66M
AORT icon
21
Artivion
AORT
$1.31B
$3.23M 1.28%
+121,178
New +$3.15M
CRGX
22
DELISTED
CARGO Therapeutics
CRGX
$3.21M 1.27%
+173,860
New +$3.11M
CNTX icon
23
Context Therapeutics
CNTX
$35.3M
$2.6M 1.03%
1,328,352
– –
ENTA icon
24
Enanta Pharmaceuticals
ENTA
$396M
$1.83M 0.73%
177,004
– –
NUVB icon
25
Nuvation Bio
NUVB
$2.34B
$1.53M 0.61%
668,115
– –
1
2 3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Sio Capital Management held 57 positions worth $252M, down 32% from $370M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sio Capital Management withdrew a net $61.6M in Q3 2024, closing 18 positions and reducing 13 holdings. Its most notable exit was Smith & Nephew, an estimated $14.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 69% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Sio Capital Management opened a new position in Teva Pharmaceuticals worth $24.3M.

  • Sio Capital Management's largest Q3 2024 buy was Teva Pharmaceuticals: 1,349,274 shares worth $24.3M.
  • Sio Capital Management added most to Compass Pathways in Q3 2024, an estimated $4.38M increase.
  • Sio Capital Management's biggest Q3 2024 reduction was Teleflex, cutting an estimated $16.8M.
  • Sio Capital Management fully exited Smith & Nephew in Q3 2024, selling an estimated $14.4M.
  • Sio Capital Management's ten largest holdings make up 68% of its $252M portfolio in Q3 2024.
  • Sio Capital Management opened 9 new positions and closed 18 in Q3 2024.
  • Sio Capital Management's portfolio value fell 32% quarter-over-quarter to $252M.

Based on Sio Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.